The influence of botulinum toxin A injections into the calf muscles on genu recurvatum in children with cerebral palsy

Clin Orthop Relat Res. 2013 Jul;471(7):2327-32. doi: 10.1007/s11999-013-2897-7. Epub 2013 Mar 6.

Abstract

Background: With cerebral palsy (CP), an equinus deformity may lead to genu recurvatum. Botulinum toxin A (BtA) injection into the calf muscles is a well-accepted treatment for dynamic equinus deformity.

Questions/purposes: The purpose of this study was to determine whether BtA injections into the calf muscles to decrease equinus would decrease coexisting genu recurvatum in children with diplegic CP.

Methods: In a retrospective study, 13 children (mean age, 5 years) with spastic diplegic CP showing equinus and coexisting primary genu recurvatum, who were treated with BtA injections into the calf muscles, were included. Evaluations were done before and 6 and 18 weeks after intervention using three-dimensional gait analysis and clinical examinations according to a standardized protocol. Basic statistical analyses (power analysis, ANOVA) were performed to compare genu recurvatum before treatment and at 6 and 18 weeks after injection with BtA.

Results: During stance phase, maximum ankle dorsiflexion was increased substantially from -3.0° ± 14.3° before to 6.2° ± 14.2° 6 weeks after the injections. Despite this, with the numbers available, the amount of recurvatum in stance did not improve with treatment at either 6 or 18 weeks. There was significant improvement of knee hyperextension during stance phase of 6.2° between baseline and 18 weeks after BtA injection, but a genu recurvatum was still present in most patients.

Conclusions: Despite improvement of ankle dorsiflexion after injection with BtA, genu recurvatum did not show relevant improvement at 6 or 18 weeks after injection with the numbers available. Because knee hyperextension remained in most patients, other factors leading to genu recurvatum should be taken into consideration. In addition, a botulinum toxin-induced weakness of the gastrocnemius may explain why recurvatum gait was not significantly reduced.

Level of evidence: Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

MeSH terms

  • Ankle Joint / drug effects*
  • Ankle Joint / physiopathology
  • Biomechanical Phenomena
  • Botulinum Toxins, Type A / administration & dosage*
  • Cerebral Palsy / complications*
  • Child, Preschool
  • Equinus Deformity / drug therapy*
  • Equinus Deformity / etiology
  • Equinus Deformity / physiopathology
  • Female
  • Gait
  • Humans
  • Injections, Intramuscular
  • Joint Deformities, Acquired / drug therapy*
  • Joint Deformities, Acquired / etiology
  • Joint Deformities, Acquired / physiopathology
  • Knee Joint / drug effects*
  • Knee Joint / physiopathology
  • Lower Extremity
  • Male
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / physiopathology
  • Neuromuscular Agents / administration & dosage*
  • Recovery of Function
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A

Supplementary concepts

  • Cerebral palsy, spastic, diplegic